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Abstract
Background: Gastrointestinal fistula (GIF) in severe acute pancreatitis (SAP) is considered as a sparse episode and
studied sporadically in the literature. There is paucity of data on the prediction of the effect on risk of GIF in patient
with SAP. This study was aimed to investigate risk factors related to GIF in the development of SAP.
Methods: The clinical data of 344 patients with SAP from 2011 to 2016 were reviewed retrospectively. All patients
were divided into the GIF group and the non-GIF group, and their data analyzed with respect to 15 parameters
were applied to explore potential risk factors for GIF in patients with SAP.
Results: Of the 344 eligible patients, 52 (15.12%) progressed to GIF. Only occurrence of infected pancreatic and
extra-pancreatic necrosis (IPN) (P = 0.004, OR = 3.012) and modified CT severity index (MCTSI) (P = 0.033, OR = 1.183)
were proved to be independent risk factors for GIF in patients with SAP, and blood type B (P = 0.048, OR = 2.096,
95% CI: 0.748–3.562) indicated weaker association of risk factor for GIF. The early (48–72 h after admission) enteral
nutrition (EEN) (P = 0.016, OR = 0.267) acted as a protective factor.
Conclusions: Occurrence of IPN and high MCTSI are independent risk factors for the development of GIF in
patients with SAP, blood type B reveals a potential correlation with GIF in patients with SAP. EEN is helpful to
prevent the progression of GIF secondary to SAP.
Keywords: Severe acute pancreatitis, Gastrointestinal fistula, Risk factor, Infected pancreatic necrosis, MCTSI, EEN,
Blood type B
Background
Severe acute pancreatitis (SAP) is a devastating disease
that is characterized by a high mortality rate (ranging from
15% to as high as 85%) due to the development of pancre-
atic and extra-pancreatic necrosis infection, and multi-
system organ failure (MOF) [1, 2]. The management of
SAP is complicated because of the incomplete under-
standing of the pathogenesis and multi-causation of the
disease, uncertainties in predicting outcome and limited
effective treatment modalities [2, 3]. Gastrointestinal fis-
tula (GIF) is a well-recognized complication secondary to
SAP, although the incidence of GIF in SAP is low and
sporadically reported in the literature. As previously re-
ported, GIF is one of the most fatal and intractable com-
plications after SAP, and associated with other major
complications and serious clinical consequences, such as
hemorrhage and exacerbation of infection which can lead
to a fatal outcome [4–7]. The etiology and pathogenesis of
GIF in patients with SAP involve complex processes,
which are far from fully understood. Indeed, the manage-
ment of GIF in SAP is complicated and controversial,
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which could lead to a prolonged hospital course, and sig-
nificant morbidity and mortality [8, 9]. The sites of fistula
may involve the stomach, duodenum, jejunum, ileum, and
colon, either in localization or diffusion. GIF may result
from direct erosion from digestive enzymes excreted by
the inflamed pancreas on the adjacent gastrointestinal
(GI) tract, or it could occur as a consequence of intestinal
necrosis due to vascular thrombosis in an area of inflam-
mation and infection. In addition, GIF may be associated
with iatrogenic intervention [10–12].
It has been reported that GIF may cause none of add-
itional symptoms in some cases, which are usually detected
incidentally on radiologic imaging or during surgical
intervention [10, 13–15]. The resulting events of GIF
we observed also confused us frequently, which led to
either further complications or spontaneous resolution.
Interestingly, more of GIF often tended to relatively facile
resolution rather than thorny complications, especially
serious GIF, such as the case of multiple or diffuse. Little
data exists regarding the risk factors for this complication,
and few publications provide precise and adequate predic-
tions of the risk for GIF in patients with SAP. Therefore,
the early prediction of GIF and specific targeted interven-
tions are imperative to reduce GIF-related mortality
[16, 17]. In this retrospective study we analyzed the data
from patients with SAP to determine the risk factors for
developing GIF. Moreover, we also studied the different




From January 2011 to January 2016, patients with a primary
diagnosis of SAP admitted to Departments of Emergency,
Hepatopancreatobiliary Surgery, Gastroenterology, Surgical
Intensive Care Units of Zhongshan Hospital (Xiamen,
China) within 72 h from the onset of the disease were
screened for enrollment, and including some critical pa-
tients confirmed SAP who transferred from other facilities.
Demographic and clinical characteristics of patients were
collected at the time of admission.
Our criteria are consistent with that recommended in
the Revised Atlanta Classification (RAC-2013) [18] and
the revised guidelines of the Italian Association for the
Study of the Pancreas (AISP-2014) [9]. To ensure the in-
clusion of only eligible patients with SAP, only those
with an acute inflammatory process of the pancreas as-
sociated with variable severity were included, such as the
presence of organ failure and local/systemic complications.
Patients who met the following criteria were excluded: (1)
patients developed GIF after iatrogenic intervention or sur-
gical management;(2) younger than 18 years old age; (3)
previous diagnosis of chronic liver and gastrointestinal dis-
ease; (4) pregnancy or severe immune system disorders; (5)
end-stage chronic disease; (6) patients with incomplete
data (e.g., deceased within 24 h after admission, missing
computed tomography (CT) diagnosis, or termination of
treatment on halfway); (7) patients with chronic pancrea-
titis, known malignancy were excluded.
Diagnosis and classification of SAP
According to RAC-2013 and AISP-2014, the diagnosis of
SAP requires clinical course, laboratory parameters and
imaging evaluation such as contrast-enhanced CT (CECT),
ultrasonography (US) and/or magnetic resonance imaging
(MRI), Endoscopic ultrasound (EUS) [19–21]. The severity
of SAP is stratified moderately severe (MSAP) and severe
(SAP). MSAP is defined as the presence of transient organ
failure (<48 h), local complications or exacerbation of co-
morbid disease. SAP is defined as persistent organ failure
(> 48 h) affecting respiration, renal function or the cardio-
vascular system. The SAP diagnosis requires at least one of
the following criteria: (a) Acute Physiology and Chronic
Health Evaluation II (APACHE II) score 8; (b) Ranson
score 3; (c) organ failure (i.e., transient and persistent); and
(d) local complications (i.e., necrosis, abscess or pseudo-
cyst) [22]. The presence of organ failure was defined by
Modified Marshall Scoring System [18, 23]. Local compli-
cations have been defined in RAC-2013, include acute pan-
creatic or peripancreatic fluid collection (APFC), acute
necrotic collection (ANC), and walled-off necrosis (WON),
pancreatic pseudocysts. IPN is defined as the presence of
infection in the development of ANCs and WONs. Other
local complications include pancreatic fistula, gastric outlet
dysfunction, splenic and portal vein thrombosis, gastro-
intestinal necrosis and fistula, hemorrhage etc [24–26].
Systemic complications are involved as exacerbation of
preexisting conditions like systemic inflammatory response
syndrome (SIRS), coronary artery disease, congestive
cardiac failure, chronic obstructive pulmonary disease,
diabetes, and chronic liver disease, precipitated by acute
pancreatitis [27]. GIF is defined as pathological communi-
cations that connect any portion of GI tract with the nec-
rotic cavity, the peritoneal space, the retroperitoneal areas,
or another internal organ. For overlapped with clinical
manifestations of pancreatitis, diagnosis of GIF is often
based on fistulography, digestive endoscopy, or operative
findings [28].
Etiologies
The etiology was considered to be of biliary origin when
biliary tract stones were detected by US, CT or magnetic
resonance cholangiopancreatography (MRCP), endoscopic
retrograde cholangiopancreatography (ERCP). Alcohol
was considered to be secondly etiological factor. For
pancreatitis due to hypertriglyceridemia (HTG), a serum
triglyceride (TG) level of more than 1000 mg/dL or
500–1000 mg/dL with a history of HTG was necessary,
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in addition to exclusion of other triggers. Lacking any of
the above evidence or other direct causes, any unexplained
pancreatitis, such as sphincter of Oddi dysfunction, preg-
nancy associated, ampullary obstruction, hyper-calcemia,
drugs related and autoimmune, were defined as idiopathic
AP in this study [29].
Clinical management protocol
Immediately after admission, all patients administrated
individualized conservative therapy for SAP that included
intensive monitoring, fluid resuscitation, oxygen adminis-
tration, fasting, analgesia and suppression of pancreatic
exocrine function by pharmacological agents, such as
somatostatin. Nasoduodenal feeding tubes were placed,
and feeding was initiated 48_120 h after admission.
EEN was defined as feeding within 48_72 h after admis-
sion. Additionally, antibiotic therapies were guided by
the results of culture and sensitivity. Rather than pre-
venting infection, antibiotics were prescribed in these
often critical patients with established infected necrosis
or the presence of other infections (e.g., biliary tract,
urinary tract, pulmonary, etc.). CECT was performed
routinely for all patients within 72 h after admission or
earlier when warranted by diagnostic dilemmas. IPN
was diagnosed according to the positive gram stain and
culture results of pancreatic or peripancreatitic necrotic
tissue obtained by means of CT guided fine needle as-
piration, or from the first percutaneous drainage or op-
eration. IPN, WON and pseudocyst with complications
were managed with a minimally invasive based step-up
approach firstly, next step was performed if there was
no clinical improvement. Nonsurgical procedures in-
cluded percutaneous drainage and continuous negative
pressure irrigation. Once GIF in patients with SAP was
confirmed, which in most cases were already at least 2
weeks after initiating EEN. Enteral nutrition (EN) was
deprived conditionally, and intra or extra-luminal drainage
(applicable for the localized GIF), or enterostomy (applic-
able for the diffuse GIF) might be performed if necessary
by the rationale of minimally invasive procedure, as well
as interventional management with a step-up approach
for SAP.
Data collection
Data pertaining to clinical characteristics, including la-
boratory parameters, imaging record, phase and location
of GIF, intervention for GIF, and outcomes were recorded.
The metrics analyzed in the present investigation included
demographic characteristics like age, gender, cause of ill-
ness, and clinical parameters such as MCTSI, APACHE II
score, C-reactive protein (CRP) level, intra-abdominal
pressure (IAP), blood type and occurrence of IPN. All the
laboratory results were obtained at the Central Laboratory
of Zhongshan Hospital according to the standard
protocols. IAP was measured with a catheter inserted
into the bladder, and patients underwent EEN were also
documented.
Statistical analysis
SPSS 22.0 software (IBM SPSS Statistics; IBM Corporation;
Armonk, NY) was used for data analysis. The distributions
of quantitative variables were tested. Normally and non-
normally distributed quantitative variables were presented
as the median (interquartile range), respectively. Continu-
ous variables were compared between the groups using an
unpaired t-test and a paired t-test within each group.
Categorical variables were compared using the Chi-square
test. For small samples, analysis of variance and Fisher’s
exact test were used to analyze continuous and categorical
variables as appropriate. Statistical significance was set at
P < 0.05.
To identify risk factors for GIF, several series of univari-
ate logistics regression analyses were performed involving
15 indices above mentioned. Variables that showed statis-
tical significance were tested in further multiple logistic
regression analyses with the stepwise method.
Results
During the observational period, 344 patients were en-
rolled in the analyses. The demographic data and clinical
characteristics of both GIF and non-GIF groups are shown
in Table 1. Of the 344 patients, GIF developed in 52 pa-
tients (15.12%) and most of the GIF cases were confirmed
clinically 4-8 weeks after onset of the disease. Table 2
shows the results of the univariate regression analysis of
GIF in SAP. Hyperlipidemia, MCTSI, APACHE II score,
EEN, B blood type and WON showed significant differ-
ence between patients with or without GIF. The results of
our study correlate well with the statistical results shown
in Table 1, which also suggests differences in respect of
these six parameters between GIF and non-GIF patients.
Taking these significant variables by univariate analysis
together into the multiple logistic regression model as
showing in Table 3, Only occurrence of IPN (P = 0.004,
OR = 3.012) and MCTSI (P = 0.033, OR = 1.183) were
proved to be independent risk factors for GIF in SAP.
EEN (P = 0.016, OR = 0.267) confirmed as a protective
factor for GIF in patients with SAP. Unfortunately, blood
type B (P = 0.048), although just marginal statistical sig-
nificance was reached, but the 95% confidence interval
(0.748–3.562) observed in the multivariate logistic re-
gression are paradoxical. Table 4 demonstrates the gen-
eral characteristics and outcome data of SAP with GIF.
Most of GIF (92.3%) occurred beyond the phase of APFC,
and diffuse GIF was rarely found in WON. All localized
GIF were managed using non-surgical procedures. Forty
of 52 fistulas closed spontaneously over time after drain-
age and the source of infection was controlled. Eight of 40
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fistulas closed spontaneously with nothing but conserva-
tive supportive management. Seven of 40 patients (17.5%)
failed to survive due to MOF or septic shock. For 10 of 12
diffuse GIF, ileostomy or colostomy was performed. Two
of them were managed by percutaneous drainage proced-
ure because the patients could not tolerate surgery. Five of
fistulas survived and seven (58.3%) died of MOF or other
serious complications. The overall mortality was 14 of 52
(26.9%).
Discussion
GIF is a well-recognized complication that occurs in the
late phase of AP. However, the clinical relevance of GIF
in patients with AP has been rarely studied by investiga-
tors, and the reported incidence ranges from 3 to 12% in
Table 1 Demographic data and clinical characteristics of the patients with SAP
Characteristic GIF (n =52) Non-GIF(n =292) Total(n = 344) P value
Age, years(range) 51 (34–77) 49(27–70) 50(27–77) 0.572
Gender, M/F 32/20 160/132 192/152 0.047
Etiology
Biliary 29 156 185
Alcohol 7 35 42
Hyperlipidemia 5 37 42
Idiopathic 11 64 75
BMI (kg/m2) 22.84(16.25–25.72) 24.13(16.93–28.32) 23.05(16.20–28.42) 0.053
EEN 10 204 214 0.001
APACHE II score 16(11–19) 10(8–15) 10(8–16) 0.035
MCTSI 8(6–10) 6(6–8) 6(6–10) 0.039
CRP level(mg/dl) 143.0(85.0–186.0) 124.6(50.6–184.3) 128.0(64.5–187.0) 0.027
Albumin 10(8–20) 14(11–24) 13(10–28) 0.046
B blood type 16 55 71 0.022
IAP(mmHg) 10.50(9–12.48) 8.50(6.35–11.50) 9.20(6.54–11.75) 0.093
ascites 30 152 182 0.419
thrombosis 9 38 47 0.181
IPN 43 137 180 0.032
death 14 62 75 0.754
M male, F female, APACHE Acute Physiology and Chronic Health Evaluation, BMI body mass index, EEN the early enteral nutrition, CRP C-reactive protein,
IAP intra-abdominal pressure, MCTSI modified CT severity index, IPN infected pancreatic and extra-pancreatic necrosis
Table 2 Univariate logistic regression analysis of GIF
Variable OR 95% CI P value
Lower Upper
Age 1.406 0.972 1.732 0.937
Gender 1.031 0.948 1.431 0.873
Alcohol 1.370 0.253 0.724 0.284
Hyperlipidemia 2.471 0.542 2.797 0.029
BMI 1.151 1.017 1.314 0.056
APACHE II score 1.632 0.951 3.118 0.044
MCTSI 4.233 1.026 4.965 0.025
CRP level 1.973 0.927 2.531 0.172
EEN 0.346 0.253 0.764 0.004
Albumin 2.427 0.862 2.253 0.122
B blood type 2.994 1.181 6.137 0.036
IAP 1.038 0.929 1.287 0.087
ascites 1.279 0.764 3.249 0.126
thrombosis 1.878 0.912 3.104 0.201
IPN 3.174 1.783 11.902 0.002
APACHE Acute Physiology and Chronic Health Evaluation, BMI body mass index,
EEN the early enteral nutrition, CRP C-reactive protein, IAP intra-abdominal
pressure, MCTSI modified CT severity index, IPN infected pancreatic and
extra-pancreatic necrosis
Table 3 Independent risk factors in a multivariate logistic
regression analysis of GIF
Variable OR 95% CI P value
Lower Upper
Occurrence of IPN 3.012 1.693 15.026 0.004
EEN 0.267 0.182 0.738 0.016
MCTSI 1.183 1.096 2.547 0.037
B blood type 1.006 0.748 3.562 0.048
IPN infected pancreatic and extra-pancreatic necrosis, EEN the early enteral
nutrition, MCTSI modified CT severity index
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different studies [28–30]. In the present retrospective
study, GIF developed in 52 of 344 patients (15.12%),
which was relatively higher than previously reported.
The higher incidence should be mainly due to screening
only SAP patients for enrollment in our study, and in
addition, some critical patients admitted to our center
who were transferred from other facilities.
We evaluated 15 potential risk factors for GIF in SAP
patients and demonstrated the occurrence of IPN result-
ing from ANC or WON and high MCTSI to be inde-
pendent risk factors (P = 0.004, OR = 3.012; P = 0.037,
OR = 1.183). EEN acted as a protective factor for GIF with
SAP (P = 0.0001, OR = 1.006). Unfortunately, our data
suggested that blood type B was also correlated with GIF
(P = 0.048, OR = 1.006), not only less strongly, but the 95%
confidence interval (0.748_3.562) was paradoxical based
on multivariate logistic regression.
Previous studies have confirmed infection of pancre-
atic necrosis can be observed in 25_70% of patients with
necrotizing disease [31]. Occurrence of pancreatic and
peripancreatic necrosis and formation of WON serve as
nidus for bacterial superinfection are prone to develop
infections which thought to be involved in the pathogen-
esis of GIF. The microbial pathogens that cause IPN in
necrotizing pancreatitis are predominantly gut-derived
[32]. A transition from a pro-inflammatory to an anti-
inflammatory response occurs within the first 1_2 weeks,
the patient is at risk for the translocation of intestinal
flora as a result of intestinal barrier failure followed by
the development of consequent IPN and fluid collections,
which is thought to be associated with severe local inflam-
matory response and may erode the blood vessel directly,
stimulate vessel spasm, enhance thrombosis, and reduce
capillary perfusion, especially, when secondary infection
occurs [33]. Inflammation or infected necrosis and en-
zyme-rich fluid can exacerbate the condition of gastro-
intestinal (GI) tract, which facilitate the formation of
oedema, thrombosis, ischemia, necrosis and resulting in
formation of fistula eventually [11]. With respect to the
time of occurrence of GIF during the course of SAP, 85%
patients had GIF beyond 4_8 weeks [34], which suggests
that the development of GIF is associated with the long-
term effects of the pancreatic or peripancreatic inflamma-
tion and infection. The finding is in agreement with our
results, as patients with IPN had a higher risk of GIF.
Hence, due to the anatomical characteristics of GI tract
and the nature of pancreatic necrosis, the region of GIF
was local or diffuse, but the underlying pathogenesis of
both were same. Timely drainage of infected necrotizing
collection could significantly decrease the risk of GIF.
For preventing infections in patients with SAP, recent
studies have universally supported the optimal strategy
of fluid resuscitation, which involves aggressive fluid ad-
ministration during the first 24h of admission, highlight
optimal targeting of individualized fluid requirements,
and utilizing lactated Ringer’s as the fluid type of pre-
ferred choice [35–37]. Additionally, routine antibiotic or
probiotic prophylaxis is recommended for patients with
SAP. Antibiotic therapy should be initiated while the
source of the infection is suspected or investigated [38].
Reliable evidence from several randomized controlled
trials and meta-analyses comparing the outcomes of EN
to parenteral nutrition (PN) in patients with AP has
clearly shown the superiority of EN in decreasing the in-
fectious complication rate, MOF, mortality, and length
of hospitalization [39]. Our data suggest that EEN, in
contrast to the maximum IPN and maximum WON
level, acts as a protective factor for GIF secondary to
SAP (P = 0.016, OR = 0.267). EN starting in the early
phase (48_72h after admission) of SAP is superior to
later EN (72 h after admission) and PN. Some studies
have demonstrated that EEN can timely deliver nutritional
support, while it preserves gut mucosal integrity, inhibits
bacterial overgrowth and translocation, supports splanch-
nic metabolism, and mitigates the systemic inflammation
and risk of infection [40, 41]. The results of a well-
designed multicentric randomized clinical trial did not
show positive effects of EEN (within 24 h after admission)
against on-demand nutrition (48 h since admission), with
the incidence of IPN as an endpoint. Conversely, feeding
within the first 24 h might act as a burden, which might
be of no benefit to prevent gut-derived infectious compli-
cations. Accordingly, it is not recommended to initiate
feeding within first 24 h, rather feeding initiated 48 h after
admission is more beneficial [42, 43]. However, SAP is al-
ways accompanied with delayed gastric emptying and in-
testinal ileus that lead to anorexia, nausea, and vomiting
that prevent the patient from tolerating oral fluids and
diet. And ventilator support executing sedation in the ICU
preclude oral feeding in patients with SAP. So EN need to
Table 4 General characteristics data of SAP with GIF
GIF style Phase Management Death
APFC INP WON operation drainage Selfhealing
Localization 2 12 26 0 32 8 7/40
diffusion 2 10 0 10 2 0 7/12
total 4 22 26 10 34 8 14/52
APFC acute pancreatic or peripancreatic fluid collection, WON walled-off necrosis, IPN infected pancreatic or peripancreatic necrosis
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be supplied via nasogastric (NG), nasoduodenal, or naso-
jejunal (NJ) feeding. In patients who have gastric outlet
obstruction from pancreatic inflammation or fluid collec-
tion related duodenal compression, a nasogastrojejunal
(NGJ) tubing system, a double lumen tube with proximal
gastric decompression, and distal jejunal feeding ports can
be used to meet both the purposes without the need for
two separate tubes [44, 45]. In our center, nasoduodenal
feeding tubes as the primary method of enteral feeding
were placed by endoscopists or radiologists, NJ and NGJ
were managed secondarily if necessary, and fluid feeding
was initiated after 48_120 h after admission.
It was confirmed in the present study that patients
with SAP and high MCTSI scores were at a higher risk
for GIF. The MCTSI is one of the most preferred modality
for severity assessment of acute pancreatitis by incorporat-
ing extra-pancreatic complications. CECT is considered
the non-invasive reference standard for diagnosing AP,
and is highly accurate in assessing IPN and its complica-
tions when performed 72–96 h after symptom onset
[24, 46]. MCTSI is credited with IPN and involvement
of pleural effusion, ascites, vascular or gastrointestinal
complications, and as expected, has the greatest accur-
acy for predicting SAP, which correlates more closely
with patient outcome in terms of duration of hospital
stay and development of organ failure [47, 48]. Because
MCTSI is intrinsically implicated with gastrointestinal
complications, which involves the potential opportunity
for occurrence of GIF. MCTSI is inevitably as a sensi-
tive risk factor for GIF in patients with SAP.
Previous reports have suggested that blood type B may
be a genetic eliciting factor for chronic autoimmune pan-
creatitis [49]. Unfortunately, our results revealed a slight
correlation between blood type B and the develop-
ment of GIF in patients with SAP. For blood type B
(P = 0.048,OR = 1.006), marginal statistical significance was
reached, but there was an ambiguity with respect to the
paradoxical 95% confidence interval (0.748_3.562) observed
in the multivariate logistic regression, which indicated a
weaker association of risk factor for GIF or implied a rela-
tively limited sample size in our study. How the intrinsic
relationship between these observed factors is confusedly
unclear. Even though our data have shown an association
between the development of GIF in patients with SAP and
blood type B, previous analyses should not be regarded
as an outcome of our study, and further investigation is
warranted.
The clinical outcomes, as illustrated in Table 4 suggest
that patients with SAP in combination with diffuse GIF
have much longer hospital stays, more severe complica-
tions, extremely poor prognosis, and require more invasive
treatments than localized counterparts, which might cause
none of additional symptoms and are even detected inci-
dentally [4, 50]. In our study, only 12 of 52 fistulas (23.1%)
were shown to be diffuse GIF, and 40 of 52 fistulas (76.9%)
were in localized GIF.
It was easy to neglect GIF because its symptom always
overlap with clinical manifestations of SAP, and visible
air pockets within the necrotic area on the imaging of
CECT are frequently confused with infection of necrosis
[51, 52]. Even diffuse GIF might not be observed timely
unless persistent deterioration aroused attention. Never-
theless, the morbidity associated with localized GIF is
significantly higher than diffuse GIF. Thus, it is not diffi-
cult to explain why there is no remarkably discrepancy
in mortality (26.92% vs. 21.23%; P = 0.754) related to the
SAP between patients with and without GIF, as shown
in Table 1. This consistency may be mainly attributed to
the following: First, the occurrence of severe intestinal
edema, ischemia, necrosis and fistula caused by erosion
and necrosis of enzyme-rich fluid and infected necrotic
tissue is most localized in the retroperitoneal space and
diffusion is limited. Therefore, most GIF of upper GI tract
can usually close spontaneously with time if the infected
source can be well controlled [12, 14]. Second, GIF can
potentially benefit the patient by draining IPN into GI
tract, especially when IPN, WON, or pseudocyst commu-
nicate with the gut [4, 53]. Third, advances in technology,
a sufficient nutrition supply, effective anti-infective treat-
ment, and timely surgical intervention have also played
extremely important roles [54].
There were two primary advantages in the present
study. First, we observed originally that blood type B is an
independent risk factor for GIF in patients with SAP, albeit
the relatively small sample of the present study might have
reduced the statistical power. Second, we attempted to
identify specific, routinely tested and reproducible baseline
clinical parameters that predict the risk factors which are
associated with GIF secondary to SAP. There were also
several limitations to our study. First, this was a retro-
spective study with a relatively limited sample size. The
actual incidence of GIF might be lower than our report
because some patients transferred to our center were crit-
ical and most had been treated in other facilities for a long
time. The non-parametric test applied may bring some
uncertainty to the conclusions. Second, the guidelines that
some experts recommended (the prophylactic administra-
tion of antibiotics and some pharmacologic agents are not
necessary in all patients with acute pancreatitis) [55–58]
were also not implemented in the present study owing to
lacking of uniform experimental assessments. Third, as a
relative contra-indication of EN, SAP was associated with
delayed gastric emptying and intestinal ileus. EEN might
be executed unsuccessfully due to subjective bias of
the individual administrator. Finally, by introducing
the updated classification of SAP, it was inevitable to
make selection bias by ruling in or out patients who
were over-or-underestimated due to the seemingly
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homologous definition. Whether or not these aspects
could affect the incidence and analysis of GIF in pa-
tients with SAP is uncertain.
Conclusion
We conclude that occurrence of IPN and higher MCTSI
are independent significant risk factors for the develop-
ment of GIF in patients with SAP. EN in 48–72 h after
admission is conformed to be an independent significant
protective factor of GIF secondary to SAP. Also the pa-
tient with blood type B is predisposed to develop GIF in
the patient with SAP, perhaps which need more support.
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